Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500) and the Nasdaq (COMP:IND) ending the week in the ...

Lilly CEO says businesses most affected by CVS move are small employers Stock reaction to CVS decision is 'overblown,' says investor Lilly tops Wall Street view for first quarter profit, revenue Lilly ...

・Lilly is reportedly shifting its 50,000 employees to Rightway, a fintech-driven pharmacy benefit manager, starting January 1. ・The move follows CVS Caremark’s decision to drop Lilly’s Zepbound from ...

Also Read: Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment In March, Novo Nordisk launched NovoCare ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS’s ...

(Reuters) -Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity drug Zepbound from the list of medicines it covers for ...

The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst day in a long, long time. On May 1, Lilly reported Q1 earnings. Afterwards, shares got beaten down ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...

(CNN) — Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major change to her prescription benefits meant the medication she ...

Despite the largest U.S. pharmacy benefit manager (PBM) knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the ...